Ibrutinib for the treatment of chronic graft-vs-host disease in pediatric hematopoietic stem cell transplant patients: A single-center experience.
Adenine
/ analogs & derivatives
Administration, Oral
Adolescent
Child
Child, Preschool
Chronic Disease
Drug Administration Schedule
Female
Follow-Up Studies
Graft vs Host Disease
/ drug therapy
Hematopoietic Stem Cell Transplantation
/ adverse effects
Humans
Immunosuppressive Agents
/ therapeutic use
Infant
Male
Piperidines
/ therapeutic use
Retrospective Studies
Treatment Outcome
Young Adult
allogeneic stem cell transplantation
cGVHD in children
ibrutinib
pediatric cGVHD
Journal
Pediatric transplantation
ISSN: 1399-3046
Titre abrégé: Pediatr Transplant
Pays: Denmark
ID NLM: 9802574
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
08
11
2019
revised:
01
02
2020
accepted:
16
02
2020
pubmed:
24
3
2020
medline:
10
4
2021
entrez:
24
3
2020
Statut:
ppublish
Résumé
cGVHD is a significant cause of morbidity and mortality after transplant. Ibrutinib has been studied as treatment for cGVHD in the adult population. Pediatric dosing and safety of ibrutinib are unknown. We conducted a retrospective review on the use of ibrutinib in 22 children with cGVHD at Cincinnati Children's Hospital Medical Center. All patients received a dose of 250 mg/m
Substances chimiques
Immunosuppressive Agents
0
Piperidines
0
ibrutinib
1X70OSD4VX
Adenine
JAC85A2161
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13692Informations de copyright
© 2020 Wiley Periodicals, Inc.
Références
Baird K, Pavletic SZ. Chronic graft versus host disease. Curr Opin Hematol. 2006;13:426-435.
MacDonald KP, Hill GR, Blazar BR. Chronic graft-versus-host disease: biological insights from preclinical and clinical studies. Blood. 2017;129:13-21.
Flowers ME, Martin PJ. How we treat chronic graft-versus-host disease. Blood. 2015;125:606-615.
Hill L, Alousi A, Kebriaei P, Mehta R, Rezvani K, Shpall E. New and emerging therapies for acute and chronic graft versus host disease. Ther Adv Hematol. 2018;9:21-46.
Jaglowski SM, Blazar BR. How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD. Blood Adv. 2018;2:2012-2019.
Miklos D, Cutler CS, Arora M, et al. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood. 2017;130:2243-2250.
Pavletic SZ, Martin P, Lee SJ, et al. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant. 2006;12:252-266.
Alsuliman T, Belghoul M, Choufi B. Ibrutinib treatment through nasogastric tube in a comatose patient with central nervous system localization of mantle cell lymphoma. Case Rep Hematol. 2018;2018:5761627.
Lee SJ, Wolff D, Kitko C, et al. Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report. Biol Blood Marrow Transplant. 2015;21(6):984-999.
Sarantopoulos S, Cardones AR, Sullivan KM. How we treat refractory chronic graft-versus-host disease. Blood. 2019;133(11):1191-1200.
Ghez D, Calleja A, Protin C, et al. Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib. Blood. 2018;131:1955-1959.
Teh BW, Chui W, Handunnetti S, et al. High rates of proven invasive fungal disease with the use of ibrutinib monotherapy for relapsed or refractory chronic lymphocytic leukemia. Leuk Lymphoma. 2019;60:1572-1575.
Pouvaret A, Guery R, Montillet M, et al. Concurrent cerebral aspergillosis and abdominal mucormycosis during Ibrutinib therapy for chronic lymphocytic leukemia. Clin Microbiol Infect. 2019;25(6):771-773.
Ahn IE, Jerussi T, Farooqui M, Tian X, Wiestner A, Gea-Banacloche J. Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib. Blood. 2016;128:1940-1943.
Kitko CL, Levine JE, Storer BE, et al. Plasma CXCL9 elevations correlate with chronic GVHD diagnosis. Blood. 2014;123:786-793.
Tvedt THA, Ersvaer E, Tveita AA, Bruserud O. Interleukin-6 in allogeneic stem cell transplantation: its possible importance for immunoregulation and as a therapeutic target. Front Immunol. 2017;8:667.